Abstract
Oxygen binding affinity of hemoglobin can be modulated by various natural and synthetic allosteric effectors. There is considerable interest in designing agents that produce low-affinity Hbs. Such agents have several potential clinical applications. The aim of this study is to show how a molecular docking strategy can be successfully used to investigate the inhibition mechanism of these synthetic compounds.